logo

For the Inventor, By the Inventor

La Chaux-de-Fonds, Switzerland

Rhizen Pharmaceuticals Sa


USPTO Granted Patents = 51



Forward Citations = 128

Loading Chart...
Loading Chart...

17 inventors (with patents filed for the assignee):

goldMedal Srikant Viswanadha (36 out of 39 patents)

silverMedal Meyyappan Muthuppalaniappan (31 out of 32 patents)

bronzeMedal Swaroop K Vakkalanka (29 out of 34 patents)

4.  Govindarajulu Babu (19 out of 22 patents)

5.  Swaroop Kumar V S Vakkalanka (15 out of 15 patents)

6.  Prashant Kashinath Bhavar (14 out of 16 patents)

7.  Dhanapalan Nagarathnam (14 out of 61 patents)

8.  Gayatri Swaroop Merikapudi (13 out of 13 patents)

9.  Swaroop K V S Vakkalanka (5 out of 6 patents)

10.  Michael S Weiss (2 out of 4 patents)

11.  Hari P Miskin (2 out of 3 patents)

12.  Peter Sportelli (2 out of 4 patents)

13.  Jayaraman Venkat Raman (2 out of 5 patents)

14.  Kanthikiran V S Varansi (1 out of 1 patent)

15.  Merikapudi Gayatri Swaroop (1 out of 1 patent)


Core Competencies:
PI3K Delta Inhibitors
Protein Kinase Modulators
Calcium Release-Activated Calcium Channel
Glutaminase Inhibitors
Immunomodulators
Anti-Inflammatory Compounds
Bicyclic Compounds
Dual Selective Inhibitors
Pharmaceutical Compositions
Chromene Derivatives
c-Met Protein Kinases
GPR-119 Modulators

51 patents:

1. 11066402 - 3,5-disubstituted-3H-imidazo[4,5-b]pyridine and 3,5-disubstituted-3H-[1,2,3]triazolo[4,5-B] pyridine compounds as modulators of c-Met protein kinases (2021-07-20),
2. 11065236 - Pharmaceutical compositions containing a PDE4 inhibitor and a PI3 delta or dual PI3 delta-gamma kinase inhibitor (2021-07-20),
3. 11020399 - Intermediates useful in the synthesis of compounds as modulators of protein kinases (2021-06-01),
4. 10981919 - Selective PI3K delta inhibitors (2021-04-20),
5. 10966977 - Combination of anti-CD20 antibody, P13 kinase-delta selective inhibitor, and BTK inhibitor to treat b-cell proliferative disorders (2021-04-06),
6. 10947244 - Forms of a PI3K delta selective inhibitor for use in pharmaceutical formulations (2021-03-16),
7. 10851107 - Dual selective P13 delta and gamma kinase inhibitors (2020-12-01),
8. 10786504 - Method of treatment and compositions comprising a dual PI3K delta-gamma kinase inhibitor and a corticosteroid (2020-09-29),
9. 10729768 - Combination of anti-CD20 antibody and PI3 kinase selective inhibitor (2020-08-04),
10. 10668051 - Modulators of calcium release-activated calcium channel (2020-06-02),
11. 10611759 - Glutaminase inhibitors (2020-04-07),
12. 10590129 - 3,5-disubstituted-3H-imidazo[4,5-B]pyridine and 3,5-disubstituted-3H-[1,2,3]triazolo[4,5-B] pyridine compounds as modulators of protein kinases (2020-03-17),
13. 10570142 - Selective PI3K delta inhibitors (2020-02-25),
14. 10538501 - Kinase modulators (2020-01-21),
15. 10442783 - 2,3-disubstituted chromen-4-one compounds as modulators of protein kinases (2019-10-15),
Rhizen Pharmaceuticals SA is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, small molecule drugs for the treatment of cancer, autoimmune and metabolic disorders. The company specializes in oncology research and has a robust pipeline of potential therapeutics in various stages of development.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Dec 23 2025

...
51 Patents

#3 in La Chaux-de-Fonds

#275 in Switzerland

#13,372 in the World

...
La Chaux-de-Fonds, Switzerland

Rhizen Pharmaceuticals Sa

Forward Citations = 128

17 inventors:

goldMedal Srikant Viswanadha (36 out of 39 patents)

silverMedal Meyyappan Muthuppalaniappan (31 out of 32 patents)

bronzeMedal Swaroop K Vakkalanka (29 out of 34 patents)

4.  Govindarajulu Babu (19 out of 22 patents)

5.  Swaroop Kumar V S Vakkalanka (15 out of 15 patents)

Please report any incorrect information to support@idiyas.com
Loading…